Treatment of opioid dependence during pregnancy Judith Martin, MD Medical Director The 14 th Street Clinic, Oakland www.14thstreetclinic.org.

Slides:



Advertisements
Similar presentations
Perinatal Substance Abuse: Methadone Maintenance Treatment Presented by: Toni Royer, MHS, NCGC, CAC-AD Executive Director, ARS Pantops Clinic.
Advertisements

Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Neonatal Abstinence Syndrome: Taking Care of Mom and Baby Heather Rodman, PharmD PGY-2 Pediatric Pharmacy Resident Peyton Manning Children’s Hospital St.
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum Module 9 Special Populations.
Fact sheet Policies and Programs to Address Drug-Exposed Newborns The use or abuse of either illegal or prescription drugs during pregnancy can have serious.
Using methadone for opiate dependence: What counselors need to know. Matthew A. Torrington, MD COMP Conference September 11, 2007.
Management of Pregnancy Opioid Addiction Treatment.
Pharmacological Treatment of Opioid Dependence during Pregnancy: Methadone and Buprenorphine Overview Karol Kaltenbach, PhD Maternal Addiction Treatment.
 John McCarthy, M.D.  Medical Director, BAART/Bi-Valley Medical Clinic, Sacramento  Associate Professor of Psychiatry, UC Davis.
Putting the Pieces Together Perspectives from an Opioid Addiction Treatment Program.
The Disease of Opioid Addiction and Medication Assisted Treatment
V.Sideri, C.Vliora, A.Daskalaki, P.Mexi-Bourna, K.Kleanthous, M.Soulioti, G. Kyrkou, N.Bournas, V.Papaevangelou 3 rd Pediatric Clinic of the University.
Sublingual Buprenorphine and Pain
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Treating opioid addiction in hospitalized medical patients Miriam Komaromy, MD, FACP Associate Director, ECHO Institute.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Medication Assisted Treatment (MAT) Issues for Women Susan F. Neshin, MD Medical Director JSAS Healthcare, Inc. Asbury Park, NJ
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Medication Assisted Treatment (MAT) in Pregnant Women
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Re-Considering Addiction Treatment How Can Treatment be More Accountable and Effective? Lessons from Mainstream Healthcare.
OPIOID SUBSTITUTION THERAPY
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
Substance Use & Abuse in Pregnancy Janet L. Mitchell, M.D., M.P.H., F.A.C.O.G. Consultant on Women’s Health Addiction Research & Treatment Corporation.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
For Pain or Not for Pain: Methadone Madness
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.
 John McCarthy, M.D.  Executive/Medical Director, Bi-Valley Medical Clinic, Sacramento.
Pregnancy and Drug Abuse Eva Janecek-Rucker. Learning Objectives 1.To develop a knowledge base of the effects of substances of abuse (e.g., alcohol, cocaine,
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Medical issues about Methadone : What the counselor needs to know
“HEROIN” Presented by: Neva Chauppette, Psy.D P.O. Box 6234, Woodland Hills, CA cell / fax CA License PSY14524
Treating Pregnant Opioid Dependent Women: Examining Buprenorphine and Methadone Hendrée E. Jones, Ph.D. Associate Professor Department of Psychiatry and.
The Counseling Center, Inc. Devoted to the prevention and treatment of alcoholism and other drug addictions. We promote opportunities for individuals and.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Treatment of Opioid Dependency in Pregnancy and Strategies to Reduce Neonatal Abstinence Syndrome.
OBJECTIVES  Learn about types of opioids and associated withdrawal symptoms  Learn what medications are available to treat opioid addiction  Understand.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Opioid Treatment Basics for Counselors Thomas E. Freese, PhD Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance Abuse Programs.
Buprenorphine {Suboxone®, Subutex®}
Buprenorphine Joseph Merrill M.D., M.P.H. University of Washington Harborview Medical Center.
Overview of the Program Medication Assisted (Supported) Treatment Michael Delman MD, FACP, FASCG, FASAM Assistant Professor of Medicine Hofstra North Shore-LIJ.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Neonatal Abstinence Syndrome
Medication Assisted Treatment for Opioid Use Disorders
Rika Dombrowski PHN, MS, MA, IBCLC. Among pregnant women years of age in U.S, -5.2% had used illicit drugs in the past month. -9.4% Alcohol use.
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Specific issues in drug use and pregnancy. Pregnant women who use drugs (RCOG, 2010) One of the challenges for pregnant women who use drugs is that they.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Gregory S. Brigham, Ph.D., CEO
Substance Exposed Newborns: Addressing Substance Use Disorder
What does pharmacology have to do with treatment of heroin addiction?
Opioid Use Disorder and pregnancy seminar
Opioid Medication Assisted Tx (1)
Medication-Assisted Therapy at Coleman Profession Services
Screening and Referral
Neonatal Abstinence Syndrome: An emerging issue for Part C systems?
Medication Assisted Treatment and Pregnancy
MEDICATION ASSISTED TREATMENT for OPIATE ADDICTION
A Training For Multidisciplinary Addiction Professionals
Medication-Assisted Treatment 101: Breaking the Stigma
Pain Management: Patients Maintained on Buprenorphine
Maintenance Treatment
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Presentation transcript:

Treatment of opioid dependence during pregnancy Judith Martin, MD Medical Director The 14 th Street Clinic, Oakland

In a nutshell: - context of medication-assisted addiction treatment. -Use of methadone and of buprenorphine in pregnancy and in the postpartum period.

Models of addiction treatment Recovery Psychodynamic Behavioral Spiritual Medical

ADDICTION AS A CHRONIC ILLNESS Chronic relapsing condition which untreated may lead to severe complications and death.

ADDICTION AS CHRONIC DISEASE: IMPLICATIONS It is treatable but not curable. Adjustment to diagnosis is part of patient’s task. There is a wide spectrum of severity.

ADDICTION AS CHRONIC DISEASE, CONT.: Retention in treatment is key. Behavior changes needed. Adherence around 30%, like asthma, diabetes, hypertension.

The 14 th Street Clinic

THE DOSING WINDOW

Counseling Staff

Medical Staff

Dose Response Time “Loaded” “High” Normal Range “Comfort Zone” “Sick” Methadone Simulated 24 Hr. Dose/Response At steady-state in tolerant patient 0 hrs. 24 hrs. Subjective w/d Objective w/d Opioid Agonist Treatment of Addiction - Payte

Number of new non-medical users of therapeutics (NSDUH, 2002)

Dose Response Time “Loaded” “High” Normal Range “Comfort Zone” “Sick” Methadone Simulated 24 Hr. Dose/Response At steady-state in tolerant patient 0 hrs. 24 hrs. “Abnormal Normality” Subjective w/d Objective w/d Opioid Agonist Treatment of Addiction - Payte trough

What is the right dose? Eliminate physical withdrawal Eliminate ‘craving’ Comfort/function: usually trough is ng/ml, peak no more than twice the trough. Not oversedated Blocking dose

“How Much???? Enough!!!” Tom Payte, MD

Ref: J. C. Ball, November 18, 1988 Slide adapted from Tom Payte

Medication-assisted treatment (MAT) for addiction during pregnancy Most evidence is related to heroin addiction vs. methadone maintenance. Relapse is the main practical issue.

PREGNANCY AND OPOID ABUSE Considered a “high risk” pregnancy. Medication: Both intake and withdrawal have fetal effects. Withdrawal effects considered more serious. Psychosocial: High motivation to change, guilt about being a ‘bad mother.’ Legal: implications related to parenting and custody.

Possible Neonatal effects of heroin Low birth weight Meconium aspiration (fetal stress) STDs Neonatal withdrawal syndrome (60-80%) Delayed effects, 4-6mos (jittery) No effect

METHADONE AND PREGNANCY Improvement in outcomes overall over heroin. Fetal growth more normal than with heroin Perinatal mortality less than with heroin NAS predictable and at least 45% need treatment Breastfeeding OK

NEONATAL WITHDRAWAL (NAS, NWS) with MMT. Predictable, usually within 72 hours of birth Treatable, opiates vs phenobarbital, etc Monitor for spasms/seizures May have trouble gaining weight at first Normal development after first year Not dose-related, split dose may be helpful.

Baby at bedside: not likely

Maternal visits are the norm

Pregnant women and MMT: Admission is expedited May be admitted even without current physical dependence Monitoring requirements intensified Education about NAS, and about avoiding withdrawal during pregnancy Education about other substances.

TALKING WITH PREGNANT PATIENTS about MMT Fear about methadone Dose-related issues CPS, legal issues Self-concept and hormones Parenting Polysubstance abuse

Medical facts for pregnant patients on MMT Good overall pregnancy outcomes with maintenance. Avoid withdrawal during pregnancy, some women need split doses. NO NUBAIN during labor! (partial agonist anesthetic) Neonatal withdrawal is treatable

Coordination of care: when the delivery happens Hospital calls OTP clinic nurse to document current methadone dose, and last date and time of ingestion. Usually regular daily dose is maintained. Patient discharged with documentation of last dose: mg, date and time dispensed, and any home medications, to bring to the clinic the next day Clinics open 365, but may have limited hours.

What is a good outcome for MAT in pregnancy? Maternal abstinence during pregnancy, with steady blood levels of methadone. Regular prenatal visits with clinician who knows about MAT and methadone. Attention to surrogate markers of fetal withdrawal (increased motion, maternal craving or withdrawal) Baby stays at least 5 days, NAS controlled. Mother continues MMT after delivery, dose may decrease, may breastfeed.

Example of good outcome: McCarthy et al: Am J Obstet Gynecol, September 1, 2005; 193(3 Pt 1): High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Retrospective case series of 81 women on MMT in Sacramento.

McCarthy et al, cont Average maternal dose 101mg, most of them split dosing. 81% negative toxicologies at birth 45% treated for NAS Subgroup with best outcome was women already on MMT who became pregnant.

MAT and pregnancy, options: Methadone maintenance is the current treatment of choice for pregnant opioid addicted women Limited studies suggest that buprenorphine may be useful, possibly even reducing neonatal withdrawal days (partial agonist). No information about prescription drug abusers (one warning about OxyContin causing NAS) Detoxification or Medically Supervised Withdrawal (MSW) requires monitoring, usually done in second trimester.

Don’t prescribe narcotics to an addicted person EXCEPT: Within the Opioid Treatment Program (specially licensed, AKA methadone clinic) Under Drug Addiction Treatment Act of 2000 (office-based use of buprenorphine)

Buprenorphine New formulation of a partial mu agonist, in sublingual tablets. New legislation (DATA 2000) enabling office opioid maintenance treatment with some restrictions. Suboxone® combined with naloxone to discourage injected abuse

Comparison of Activity Levels

Por cortesía de Reckitt Benkiser

Buprenorphine and pregnancy Case series in France: safe and effective, possibly reducing NAS One preliminary study in US: Jones et al; Drug Alcohol Depend, July 1, 2005; 79(1): Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Jones et al, 2005, cont Head to head randomized blinded comparison between methadone and buprenorphine in pregnant women Women admitted during second trimester One statistically significant finding: shorter stay for bup Other trends for bup: fewer infants treated for NAS, less NAS medication used. Multi-site trial in progress now.

Practical considerations about buprenorphine and pregnancy Labeled category C (not enough information) Probably better to use mono product Informed consent for legal reasons Label says no breastfeeding, but probably safe ( not orally very bio - available) In the initial survey of use of buprenorphine, women with prescription opioid abuse were a significant population.

What about detoxification and MSW? First and third trimester generally considered more dangerous Studies show if inpatient, monitored can technically be achieved safely Practical consideration is relapse.

Summary: Opioid addiction and pregnancy Methadone maintenance is still the treatment of choice and standard of care in the US. Buprenorphine treatment is possible, evidence still lacking. Detoxification is relatively contraindicated unless done in hospital with monitoring.